Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
89 hedge funds and large institutions have $373M invested in Avadel Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 29 reducing their positions, and 21 closing their positions.
133% more call options, than puts
Call options by funds: $2.85M | Put options by funds: $1.22M
0% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 29
8% less funds holding
Funds holding: 97 → 89 (-8)
25% less capital invested
Capital invested by funds: $500M → $373M (-$127M)
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$12.8M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$7.39M |
| 3 |
SAM
Senzar Asset Management
New York
|
+$6.88M |
| 4 |
Morgan Stanley
New York
|
+$6.37M |
| 5 |
FPC
Falcon Point Capital
San Francisco,
California
|
+$5.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$13.9M |
| 2 |
Jennison Associates
New York
|
-$11.9M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$9.91M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$5.71M |
| 5 |
CPIM
Columbia Partners Investment Management
Alexandria,
Virginia
|
-$3.99M |
AVDL Hedge Fund Activity: Q4 2015 in Review
89 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2015, worth a combined $373M — down 25% from $500M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AVDL and 13 opened new positions — a net loss of 8 holders — while 29 trimmed existing stakes and 29 added.
The largest buyer was Bank of New York Mellon, adding an estimated $12.8M. The largest seller was Kennedy Capital Management, cutting an estimated $13.9M.
- 89 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2015, down from 97 in Q3 2015.
- Funds reported $373M of Avadel Pharmaceuticals stock for Q4 2015, down 25% quarter-over-quarter.
- 13 funds opened new Avadel Pharmaceuticals positions in Q4 2015 and 21 closed out, a net change of -8 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2015 was Bank of New York Mellon, an estimated $12.8M added.
- The largest Avadel Pharmaceuticals seller in Q4 2015 was Kennedy Capital Management, an estimated $13.9M sold.
Based on aggregated 13F filings for Q4 2015.